Dr Sara Vigh, MD in Huntsville, UT - Pediatrics

Dr Sara Vigh, MD is a Pediatrics physician based in Huntsville, Utah. Dr Sara Vigh is licensed to practice in Utah (license number 168891-1205) and her current practice location is 9121 E 1000 N, Huntsville, Utah. She can be reached at her office (for appointments etc.) via phone at (801) 745-3426.

NPI number for Dr Sara Vigh is 1194054361 and her current mailing address is 9121 E 1000 N, Huntsville, Utah. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1194054361.

Contact Information

	Dr Sara Vigh, MD
	9121 E 1000 N, Huntsville, UT 84317-9643
	(801) 745-3426
	(801) 745-3426

Physician's Profile

Full Name	Dr Sara Vigh
Gender	Female
Speciality	Pediatrics
Location	9121 E 1000 N, Huntsville, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1194054361
Provider Enumeration Date: 12/16/2009
Last Update Date: 12/16/2009

Medical Identifiers

Medical identifiers for Dr Sara Vigh such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1194054361	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208000000X	Pediatrics	168891-1205 (Utah)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Sara Vigh is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Sara Vigh, MD 9121 E 1000 N, Huntsville, UT 84317-9643 Ph: (801) 745-3426	Dr Sara Vigh, MD 9121 E 1000 N, Huntsville, UT 84317-9643 Ph: (801) 745-3426

News Archive

Babies with low or high birth weight may be at increased risk for developing NAFLD, study suggests

A study published in the Journal of Pediatrics suggests that children born with lower or higher weight than normal may be at increased risk for developing nonalcoholic fatty liver disease.

Peramivir shows promise for H5N1 protection

The antiviral drug peramivir might offer humans significant protection during a pandemic of the avian influenza virus H5N1, according to results of mouse studies conducted by investigators at St. Jude Children's Research Hospital.

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.

Yale study finds bullying as common factor in LGBTQ youth suicides

Researchers at the Yale School of Public Health have found that death records of LGBTQ youth who died by suicide were substantially more likely to mention bullying as a factor than their non-LGBTQ peers.

Dr Sara Vigh, MD - Pediatrics in Huntsville, UT